Immunotherapy for bladder cancer

Request an Appointment
Print

Departments and specialties

Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery.

Departments with related expertise

Areas that research this procedure

Doctors who perform this procedure

Edit search filters
close

Narrow your search

  1. There are no doctors whose last name begins with the letter A
  2. There are no doctors whose last name begins with the letter B
  3. There are no doctors whose last name begins with the letter C
  4. There are no doctors whose last name begins with the letter D
  5. There are no doctors whose last name begins with the letter E
  6. There are no doctors whose last name begins with the letter F
  7. There are no doctors whose last name begins with the letter G
  8. There are no doctors whose last name begins with the letter H
  9. There are no doctors whose last name begins with the letter I
  10. There are no doctors whose last name begins with the letter J
  11. There are no doctors whose last name begins with the letter K
  12. There are no doctors whose last name begins with the letter L
  13. There are no doctors whose last name begins with the letter M
  14. There are no doctors whose last name begins with the letter N
  15. There are no doctors whose last name begins with the letter O
  16. There are no doctors whose last name begins with the letter P
  17. There are no doctors whose last name begins with the letter Q
  18. There are no doctors whose last name begins with the letter R
  19. Find a doctor whose last name begins with the letter S
  20. Find a doctor whose last name begins with the letter T
  21. There are no doctors whose last name begins with the letter U
  22. There are no doctors whose last name begins with the letter V
  23. There are no doctors whose last name begins with the letter W
  24. There are no doctors whose last name begins with the letter X
  25. There are no doctors whose last name begins with the letter Y
  26. There are no doctors whose last name begins with the letter Z
Reset all filters

Displaying 1-2 out of 2 doctors available

  1. Paras H. Shah, M.D.

    Paras H. Shah, M.D.

    1. Urologist
    2. Oncologist
    1. Rochester, MN
    Areas of focus:

    Nephrectomy, Partial nephrectomy, Laparoscopic kidney surgery, Laparoscopic surgery, Robotic prostatectomy, Robotic sur...gery, Urinary diversion, Prostatectomy, Bladder removal, Immunotherapy for bladder cancer, Benign prostatic hyperplasia, Prostate cancer, Bladder cancer, Kidney cancer, Ureteral cancer, Urothelial carcinoma, Metastatic bladder cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

  2. Mark D. Tyson, II, M.D., M.P.H.

    Mark D. Tyson, II, M.D., M.P.H.

    1. Urologist
    1. Phoenix, AZ
    Areas of focus:

    Neobladder reconstruction, Orchiectomy, Urinary conduit surgery, Bladder removal, Retroperitoneal lymph node dissection... for testicular cancer, Immunotherapy for bladder cancer, Bladder cancer surgery, Bladder cancer, Testicular cancer, Ureteral cancer, Urethral cancer, Urothelial carcinoma, Metastatic bladder cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

Research Profiles

Edit search filters
close

Narrow your search

View all physicians • All Locations

By Mayo Clinic Staff
Request an appointment
About
Sept. 23, 2026
Print
  1. Keytruda (pembrolizumab) (prescribing information). Merck Sharp & Dohme LLC; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287. Accessed Aug. 11, 2026.
  2. TICE BCG (prescribing information). Merck Sharp & Dohme LLC; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a. Accessed Aug. 11, 2026.
  3. Flaig TW, et al. Bladder cancer, Version 1, 2026. NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0022.
  4. SEER Program Coding and Staging Manual 2026: Appendix C, coding guidelines for bladder. 2026. National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/manuals/2026/appendixc.html. Accessed Aug. 11, 2026.
  5. Chemotherapy and you: Support for people with cancer. National Cancer Institute. https://www.cancer.gov/publications/patient-education/chemo-and-you. Accessed Aug. 11, 2026.
  6. Padcev (prescribing information). Astellas Pharma US, Inc.; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed. Accessed Aug. 11, 2026.
  7. De Santis M, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. The Lancet. 2025; doi:10.1016/S0140-6736(25)01897-5.
  8. Bavencio (prescribing information). EMD Serono, Inc.; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118. Accessed Aug. 11, 2026.
  9. Van der Heijden MS, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. New England Journal of Medicine. 2023; doi:10.1056/NEJMoa2309863.
  10. Imfinzi (prescribing information). AstraZeneca Pharmaceuticals LP; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3. Accessed Aug. 11, 2026.
  11. Opdivo (prescribing information). Bristol-Myers Squibb Company; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394. Accessed Aug. 11, 2026.
  12. Anktiva (prescribing information). Altor BioScience, LLC; 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff. Accessed Aug. 11, 2026.
  13. Heiss BL, et al. FDA approval summary: Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ. Clinical Cancer Research. 2025; doi:10.1158/1078-0432.CCR-25-1231.
  14. Holzbeierlein JM, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. The Journal of Urology. 2024; doi:10.1097/JU.0000000000003846.
  15. Bladder cancer treatment (PDQ) — Health Professional Version. National Cancer Institute. Updated May 2, 2025. https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Accessed Aug. 11, 2026.
  16. Necchi A, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. The Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00178-5.
  17. Powles T, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2408154.
  18. Galsky MD, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. New England Journal of Medicine. 2026; doi:10.1056/NEJMoa2601486.
  19. Vulsteke C, et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. New England Journal of Medicine. 2026; doi:10.1056/NEJMoa2511674.
  20. Galsky MD, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. Journal of Clinical Oncology. 2025; doi:10.1200/JCO.24.00340.
  21. Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2312117.
  22. Powles T, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after 2 years of follow-up. Journal of Clinical Oncology. 2023; doi:10.1200/JCO.22.01792.
  23. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). American Urological Association. https://helpdesk.auanet.org/hc/en-us/articles/40948838469143-Guidelines. Accessed Aug. 11, 2026.
  24. Medical review (expert opinion). Mayo Clinic. Sept. 18, 2026.

Related

Immunotherapy for bladder cancer